Ireland
--:--IST
Latest
Clinical Trials in France / NCT05146180
Recruiting Not applicable

Interest of Parametric Positron Emission Imaging in the Diagnosis of Infections on Cardiac Valve Prosthesis

NCT05146180 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-02-24
Last updated
2026-01-02

Condition(s) studied

Endocarditis

Investigational drug(s) / intervention(s)

Parametric positron emission computed tomography

Parametric positron emission computed tomography: Patients will undergo parametric positron emission computed tomography in 15 days after the labeled polynuclear scintigraphy

Study summary

The objective of this study is to determine if early parametric positron emission computed tomography is useful to diagnose cardiac prosthetic valve infections.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age superior to18 years, * Effective contraception for women of childbearing age or negative pregnancy test on the day of the exam * Good general condition. WHO ≤ 1 * Suspicion of endocarditis on a prosthetic heart valve implanted more than 3 months ago * Labeled polynuclear scintigraphy performed within a maximum of 15 days before positron emission computed tomography * Standard positron emission computed tomography planned as part of the extension assessment * Informed and signed consent before any specific study procedure. * Patient affiliated to the social security system Exclusion Criteria: * Presence of an active cancer in the previous three years * Pregnancy or breastfeeding * Poorly controlled diabetic patients * Protected adults (under guardians or curators) * Impossible decubitus (orthopnea, ...), * Hypersensitivity to FDG or to one of the excipients of the radiopharmaceutical.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre Henri Becquerel Rouen France Recruiting

More Centre Henri Becquerel trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05146180 on ClinicalTrials.gov ↗ ← All trials in France